Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Entrada Therapeutics Inc (TRDA)
Entrada Therapeutics Inc (TRDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 447,131
  • Shares Outstanding, K 33,368
  • Annual Sales, $ 0 K
  • Annual Income, $ -94,620 K
  • 60-Month Beta -0.55
  • Price/Sales 5.16
  • Price/Cash Flow N/A
  • Price/Book 1.75
Trade TRDA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate 0.21
  • Low Estimate -0.53
  • Prior Year -0.79
  • Growth Rate Est. (year over year) +79.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.75 +24.65%
on 11/22/23
17.58 -23.78%
on 11/15/23
-2.10 (-13.55%)
since 11/01/23
3-Month
10.75 +24.65%
on 11/22/23
17.58 -23.78%
on 11/15/23
-2.01 (-13.04%)
since 09/01/23
52-Week
9.32 +43.78%
on 02/16/23
21.64 -38.08%
on 12/08/22
-4.27 (-24.17%)
since 12/01/22

Most Recent Stories

More News
3 Biotech Stocks to Buy to Help the Health of Your Portfolio

Amid the dynamic biotech landscape, the sector is set to witness substantial growth fueled by multiple advancements. Hence, fundamentally strong biotech stocks ANI Pharmaceuticals (ANIP), Exelixis (EXEL),...

ANIP : 50.57 (+1.53%)
EXEL : 21.94 (+0.60%)
TRDA : 13.40 (+3.32%)
3 Biotech Stocks for Long-Term Value

With medical innovations and a rising geriatric population, biotech stocks have garnered significant attention. Thus, sound biotech stocks like Genfit (GNFT), Entrada Therapeutics (TRDA), and MacroGenics...

GILD : 77.65 (+1.37%)
GNFT : 3.26 (+2.02%)
MGNX : 8.38 (+2.07%)
TRDA : 13.40 (+3.32%)
Moderna (MRNA) and 2 More Biotech Stocks That Are Worth Watching

Growing demand for personalized medicines and rising adoption of machine learning tools are expected to boost the biotech industry. Therefore, it could be wise to watch fundamentally strong biotech stocks...

FOLD : 11.22 (+1.81%)
IMTX : 9.01 (+1.92%)
MRNA : 79.83 (+2.74%)
TRDA : 13.40 (+3.32%)
3 Top Biotech Stocks to Purchase Right Away

The ever-rising demand for quality healthcare is expected to benefit the biotech industry. Moreover, favorable government initiatives to boost domestic biotech research and production should boost the...

FOLD : 11.22 (+1.81%)
SGIOY : 11.9300 (+1.71%)
TRDA : 13.40 (+3.32%)
XBI : 77.83 (+3.06%)
2 Biotech Stocks to Buy, 1 to Sell Now

The biotech industry is well-positioned for long-term growth thanks to increasing demand for quality healthcare, a rapidly aging population, and rising chronic diseases. Therefore, buying fundamentally...

FDMT : 13.28 (+4.40%)
PRQR : 1.7300 (+11.61%)
TRDA : 13.40 (+3.32%)
Are These 3 Biotech Stocks Good Buys?

Given that the biotech sector is rapidly expanding with robust demand, technology advancements, and government initiatives, fundamentally strong biotech stocks Incyte (INCY), Corcept Therapeutics (CORT),...

CORT : 25.97 (+1.96%)
INCY : 54.02 (-0.59%)
TRDA : 13.40 (+3.32%)
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings

Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.

VRTX : 351.16 (-1.03%)
CRSP : 68.65 (+2.88%)
TRDA : 13.40 (+3.32%)
MRNA : 79.83 (+2.74%)
GILD : 77.65 (+1.37%)
AMGN : 272.45 (+1.04%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such...

TRDA : 13.40 (+3.32%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such...

TRDA : 13.40 (+3.32%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such...

TRDA : 13.40 (+3.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 15.07
2nd Resistance Point 14.48
1st Resistance Point 13.94
Last Price 13.40
1st Support Level 12.80
2nd Support Level 12.21
3rd Support Level 11.67

See More

52-Week High 21.64
Fibonacci 61.8% 16.93
Fibonacci 50% 15.48
Fibonacci 38.2% 14.03
Last Price 13.40
52-Week Low 9.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar